Mary Beth Harler - 14 Aug 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: IGMS
Reported as of: 14 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2025, 17:23:40 UTC
Prior SEC filing: 25 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Mary Beth Harler

Key filing fact

Mary Beth Harler filed Form 4 for IGM Biosciences, Inc. (IGMS) on 14 Aug 2025.

Key facts

This page summarizes Mary Beth Harler's Form 4 filing for IGM Biosciences, Inc. (IGMS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 17:23.

Change

Previous filing in this sequence was filed on 25 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002018699 Primary reporting owner

Harler Mary Beth

Relationship: Chief Executive Officer, Director
Address: C/O IGM BIOSCIENCES, INC., 3 EAST THIRD AVENUE, SUITE 200, SAN MATEO
Signature: /s/ Mary Beth Harler
Signature date: 14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IGMS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -323,680
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mary Beth Harler is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock, and each outstanding RSU, was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.